

KFIN/GXP/SEP/2021 October 5, 2021

Mr. Ajay Nadkarni M/s. GlaxoSmithKline Pharmaceuticals Limited Dr. Annie Besant Road Worli Mumbai-400025.

Sub : Investor Grievance Certificate for the quarter ended September 30, 2021.

Dear Sir,

With reference to the above, we are pleased to furnish below the status of the Investor complaints under SEBI (Listing Obligations & Disclosure requirements), Regulations, 2015 for the quarter ended September 30, 2021.

Description of	Opening Balance	Received during the	Attended/Resolved	Pending as on
Complaint	as on 01.07.2021	Period 01.07.2021 to	during the Period	30.09.2021
		30.09.2021	01.07.2021 to	
			30.09.2021	
Non-receipt of	NIL	20	20	NIL
Dividend				
Non-receipt of	NIL	NIL	NIL	NIL
Annual reports				
Non receipt of share	NIL	02	02	NIL
certificates				
SEBI	NIL	NIL	NIL	NIL
Stock Exchange	NIL	02	02	NIL
Total	NIL	24	24	NIL

This is for your information and record.

Thanking you,

Yours faithfully For KFin Technologies Private Limited

Rajitha Cholleti Asst. General Manager

KFin Technologies Private Limited

(Formerly known as "Karvy Fintech Private Limited")

**Registered & Corporate Office** 

Selenium Building, Tower-B, Plot No- 31 & 32, Financial District, Nanakramguda, Serilingampally, Hyderabad, Rangareddi, Telangana, India, 5000 Ph : +91 40 6716 2222, 7961 1000 | https://www.kfintech.com | CIN : U72400TG2017PTC117649